Skip to main content
padlock icon - secure page this page is secure

Open Access University College London – Translational Research Office

Download Article:
 Download
(PDF 336.4 kb)
 
Help progress science and biomedical research discoveries along the development pathway to patient benefit. Offer academics assistance with: defining development and regulatory strategy; building and managing links to available resources; funder liaising and reporting requirements; managing risks and issues, follow-on funding and on-going project management and support. Bridge the gap between academia and the commercial healthcare sector by de-risking UCL's novel science a team of 24 highly experienced industrial translational scientists tasked with establishing the organisational culture, capability and processes necessary to deliver the UCL and BRC's mission of "Accelerating translation for health and wealth". The TRO supports the development of early stage research from across UCL and its partner hospitals, into projects attractive for translational funding or further development with partners and nurture access to complementary capacity, expertise and skills in translational science. The TRO achieves this through the integrated activities of three specialist groups a Drug Discovery Group (DDG) provides expert advice and practical support for small molecule drug discovery projects across UCL; a Translational Research Group who provide experienced project leaders to guide projects (gene, cell and regenerative medicine therapies, devices, diagnostics, small molecules) through their development; and an Industrial Partnerships Group who initiate and manage relationships with industry. The team have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, enhancing projects to optimise the chances of long-term success and benefit to patients.
No References for this article.
No Supplementary Data.
No Article Media
No Metrics

Keywords: ADVANCED THERAPY; ASSAY BIOLOGY; BIOLOGIC; BIOMEDICAL TRANSLATION; BUSINESS PARTNERSHIP; COMPANY ENGAGEMENT; DEVICE; DIAGNOSTIC; DRUG DEVELOPMENT; DRUG DISCOVERY; INDUSTRY/ACADEMIA STRATEGIC ALLIANCES; INNOVATION; MEDICINAL CHEMISTRY; PRECLINICAL TO EARLY PHASE CLINICAL TRANSLATION; PROJECT LEADERSHIP; REPURPOSING; RESEARCH PROJECT MANAGEMENT; SMALL MOLECULE; STRATEGIC ALLIANCES; THERAPEUTICS; TRANSLATIONAL RESEARCH OFFICE; TRO; UCL; UNIVERSITY COLLEGE LONDON

Document Type: Research Article

Publication date: December 1, 2018

More about this publication?
  • Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.

  • Subscribe to this Title
  • Terms & Conditions
  • Disseminating research in Impact
  • Information about Impact
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more